Kala Pharmaceuticals, Inc. (KALA) Stock Plummeting in Pre-Market, Here’s the Cause – News Heater
Home  »  Analyst Insight   »  Kala Pharmaceuticals, Inc. (KALA) Stock Plummeting...

Kala Pharmaceuticals, Inc. (KALA) Stock Plummeting in Pre-Market, Here’s the Cause

Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company, has plunged a decrease of 14.78 percentage points in the pre-market trading session. As a result, the stock was trading at $0.98 when last checked. Kala pharmaceuticals are continuing upon the momentum it gained during Tuesday’s regular trading session when it went berserk and soared by 88.49% to close the day at $1.15. The precipitous decline came after the company announced that EYSUVIS® is covered on UnitedHealthcare Commercial and Cigna Medicare.

EYSUVIS Coverage by UnitedHealthcare

On Tuesday, KALA announced the addition of EYSUVIS on UnitedHealthcare as a covered brand. The coverage would become effective from March 2022. UnitedHealthcare is among the largest commercial healthcare plans in the US. After the coverage from UnitedHealthcare, EYSUVIS would cover 118 million lives, or in percentage terms, 70% of all of the commercial lives.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Addition of EYSUVIS with Cigna Medicare

Alongside that, KALA also announced the addition of EYSUVIS on Cigna Medicare as a preferred brand. The addition became effective from February 2022. The company said that the development would cause the addition of 1.9 million Medicare lives. After the addition, EYSUVIS would have Medicare preferred coverage for select plans with Express Scripts, Cigna, and Prime Therapeutics. EYSUVIS has a total Medicare coverage of 7.1 million lives.

Comments from COO of KALA

Todd Bazemore, President and Chief Operating Officer of KALA, commented on the development that the announcements mark a significant growth on the goal of the company which relates to expansion in access for EYSUVIS for the people who battle dry eye disease. The company is looking forward to the positive engagement with other medical and health plans to execute the goal of provision of broader access of market to EYSUVIS.

What’s Next for KALA Stock?

Looking ahead, analysts are of the view that even though KALA stock holds several positive signals, they are not enough for it to be considered for buying. Hence, at the current level, the stock should be considered a hold candidate while waiting for further developments.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam